Clinical review report : Erenumab (Aimovig) (Novartis pharmaceuticals Canada Inc.) : indication: for prevention of migraine in patients who have had at least four migraine days monthly / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource.

Edition:

Final edition.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month.

Contents:

Abbreviations

Executive Summary

Introduction

Results and Interpretation

Conclusions

Disease Prevalence and Incidence

Standards of Therapy

Drug

Objectives and Methods

Objectives

Methods

Results

Findings from the Literature

Included Studies

Exposure to Study Treatments

Critical Appraisal

Efficacy

Harms

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Patient Input Summary

Appendix 2. Literature Search Strategy

Appendix 3. Excluded Studies

Appendix 4. Detailed Outcome Data

Appendix 5. Validity of Outcome Measures

Appendix 6. Summary of Other Studies, Part I

Appendix 7. Summary of Other Studies, Part II

Appendix 8. Summary of Indirect Comparisons

References.

Notes:

Description based on publisher supplied metadata and other sources.